10.antiendomsial antibody tissue transglutaminase Moderated discussion and help for gluten free, coeliac, celiac, wheat allergies or intolerance, Cookery and recipes

antiendomsial antibody tissue transglutaminase: from annette on 2006-05-05

Does anyone out there know anything about this antiendomysial antibody tissue transglutaminase. I have to have a special blood test to see if I have this.
I tried looking it up to see exactly what it is and is it survivable? From what I am finding out it is fatal. I saw one article with chemotherapy a person can survive 1 year.
I am very scared. I have had diarreha for 1 month now of and on through out the days. I do not have gas. I don't feel bloated. 1 month ago I had severe stomach pain and my doctor treated me for gastritis. My GI Dr. said she didn't want to see me til 2008. I have had celiac for 4 years now. Does anyone see their specialist more than every 6 years?
I am hoping it is stress. I am going through a divorce after 22 years of marriage and I am losing my home due to the father of my children not paying the mortgage for 5 months. Trying to hurry up and get out of here, raising 2 minors and scattering to find a place to go is very stressful. I have also lived with IBS for 14 years before being diagnosed properly. I am sure that did a lot of damage.
Please give me some good news.
I am nervous.
annette

antiendomsial antibody tissue transglutaminase: from Peter on 2006-05-05

Serological screening for antibodies against gliadin, endomysium, or tissue transglutaminase before the diagnostic biopsy is done is well established practice in patients with suspected coeliac disease.

It is a simple test to see if you have the antibodies that are indicators of the coeliac condition. Nothing more.

antiendomsial antibody tissue transglutaminase: from laura wilson on 2006-06-02

what is the half life of Anti-transglutaminase in the body. I have a client who has been using a gluten free diet x 5 months (with no celiac diagnosis) can we still test for this antibody and get a valid result.

antiendomsial antibody tissue transglutaminase: from on 2006-06-03

Persistence of Anti-transglutaminase on a totally gluten-free diet sems to vary considerably from patient to patient. The following paper examined this for 42 patients. 80\% were positive at initial diagnosis, but only 32\% after 6 months GF diet.

2003 Nov-Dec; 37(5) 387-91
Additional Info United States
Standard No ISSN 0192-0790 (Print); NLM Unique Journal Identifier 7910017
Language English
Abstract Gluten-free diet (GFD) plays a key role in the treatment of celiac disease (CD), but it is difficult to evaluate the effect of GFD on the improvement of villous architecture using sensitive, non-invasive tests. Aim of this study is to evaluate anti-transglutaminase (tTG) antibodies in the follow-up of CD to detect histologic recovery. We studied 42 consecutive patients with CD. In all the patients anti-tTG antibodies (evaluated by the enzyme linked immunosorbent assay method) and EGDscopy with multiple bioptic samples before GFD and then 6, 12, and 18 months after GFD were evaluated. For comparison, a sorbitol H2-breath test (H2-BT) and anti-endomysium (EMA) antibodies test were carried out concomitantly. Anti-tTG results were positive in 36 of 42 patients before GFD (80.95\%), while they were positive in 11 of 34 (32.35\%), 1 of 17 (5.88\%), and 0 of 6 (0\%) of patients with a persistence in histologic lesions 6, 12, and 18 months of GFD respectively, without any correlation with persistence of histologic lesions (P = NS). Also EMA failed to show correlation with improvement of histologic lesions. They were positive in 31 of 42 patients before GFD (73.80\%), while they were positive in 18 of 34 (52.94\%), 3 of 17 (17.64\%), and 0 of 6 (0\%) cases 6, 12, and 18 months of GFD respectively (P = NS). Regarding sorbitol H2-BT, it was positive in 40 of 42 (95.24\%) patients before GFD, while it was positive in 31 of 34 (91.17\%), 13 of 17 (76.47\%), and 4 of 6 (50\%) of patients with a persistence in histologic lesions 6, 12, and then 18 months after GFD starting (see Fig. 2, infra). So, anti-tTG and EMA were ineffective in assessing the histologic recovery at each follow-up visit (P = NS), while sorbitol H2-BT seems more effective than anti-tTG and EMA in this field (P < 0.0001 sorbitol H2-BT versus anti-tTG and versus EMA at 18 months after gluten withdrawal). Thirty-eight of 42 (90.47\%) patients adhered to a strict GFD. Four patients were found to have occasional dietary transgression, and in all we noted a progressive decreasing of anti-tTG after 6 months of GFD and negative anti-tTG after 12 months of GFD, but sorbitol H2-BT persisted being positive during the entire follow-up. Intestinal damage persisted during the follow-up, despite anti-tTG and EMA negativity, and worsened in the presence of dietary lapses. Anti-tTG does not seem effective to assess histologic recovery in the follow-up of celiac patients after they have started GFD due to its poor correlation with histologic damage.